[Experience with induced hypertension chemotherapy for lung cancer].
Induced hypertension chemotherapy (IHC) using angiotensin II was applied for patients with lung cancer who had not been treated previously, and the results compared with those of preceding conventional chemotherapy as a sequential control. Twenty-nine patients with non-small cell lung cancer (non-SCLC) were treated with MTX and MMC. Response rate among evaluable cases was 23.1% (3/13) for conventional chemotherapy and 18.2% (2/11) for IHC. Twenty-eight patients with small cell lung cancer (SCLC) were treated with VCR, CPA and ACNU. Among evaluable cases, both chemotherapy groups with and without IHC showed the same response rate, 66.7% (8/12). With respect to response rate, there were no differences between conventional chemotherapy and IHC for non-SCLC or SCLC.
Yano
H
H
Nishiwaki
Y
Y
Hayashibe
A
A
Honda
R
R
Hino
M
M
Kitaya
T
T
Matsuyama
T
T
Kakinuma
R
R
D000230:Adenocarcinoma / Q000628:therapy; D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D018288:Carcinoma, Small Cell / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage
D008937:Mitomycins; D000804:Angiotensin II; D016685:Mitomycin; D008727:Methotrexate